Hypermethylation of EPCAM was restricted to Lynch syndrome colorectal cancers (30% versus 0% in the sporadic groups; P < 0.001). DLC1 hypermethylation was characteristic of sporadic MSI colorectal cancer as compared to Lynch (28% versus 0% detected by the DLC1 probe, P < 0.01) or sporadic MSS colorectal cancer (28% versus 5% detected by the DLC1_i4 probe, P < 0.01). Here, EPCAM is linked to colorectal cancer.